Overview
Vascular device provider's Q4 sales rose 16%, beating analyst expectations
Diluted EPS for Q4 increased 39%, driven by higher ASPs and manufacturing efficiencies
Company announced $100 mln share repurchase program and 25% dividend increase
Outlook
LeMaitre Vascular expects Q1 2026 sales between $65.6 mln and $67.6 mln
Company forecasts full-year 2026 sales at $276 mln to $284 mln
LeMaitre Vascular projects Q1 2026 EPS between $0.64 and $0.69
Result Drivers
PRODUCT LINE GROWTH - Grafts, valvulotomes, and carotid shunts drove Q4 sales growth, with increases of 27%, 20%, and 18% respectively
REGIONAL SALES INCREASE - EMEA sales rose 29%, APAC 20%, and the Americas 10%, contributing to overall sales growth
MARGIN IMPROVEMENT - Gross margin increased to 71.7% due to higher average selling prices and manufacturing efficiencies
Company press release: ID:nGNX8vyq8v
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Sales | Beat | $64.45 mln | $62.82 mln (11 Analysts) |
Q4 Net Income | $15.58 mln | ||
Q4 Gross Profit | $46.19 mln | ||
Q4 Income From Operations | $18.83 mln | ||
Q4 Pretax Profit | $20.30 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for LeMaitre Vascular Inc is $108.00, about 19% above its February 24 closing price of $90.75
The stock recently traded at 35 times the next 12-month earnings vs. a P/E of 35 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)